ArticlePloS one2016
The Success of a Universal Hepatitis B Immunization Program as Part of Thailand's EPI after 22 Years' Implementation.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Hepatitis B Virus in West African Children: Systematic Review and Meta-Analysis of HIV and Other Factors Associated with Hepatitis B Infection.International journal of environmental research and public health · 2023Pooled it
- Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis.Journal of nephrology · 2020Pooled it
- Strategies for prevention of gastrointestinal cancers in developing countries: a systematic review.Journal of global health · 2017Pooled it
- Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.The New England journal of medicine · 2018Trial
- Long-term immune protection after infant hepatitis B vaccination in children.Human vaccines & immunotherapeutics · 2026Review
- National guideline for hepatitis B elimination in Thailand: a decentralized health system model for expanding diagnosis and treatment.Hepatology international · 2026Article
- Achieving Hepatitis C Micro-Elimination in a High-Burden Province of Thailand: The Phetchabun Model.Tropical medicine and infectious disease · 2026Article
- Community-based integrated care for HIV, viral hepatitis and sexually transmitted infections, Thailand.Bulletin of the World Health Organization · 2026Article
- Willingness to accept the HBV vaccine and related factors: Administering the vaccination attitudes examination scale to Urban Vietnamese adults.PLOS global public health · 2026Article
- Seroprevalence of antibodies to hepatitis A, B and C viruses across all age groups in Chonburi Province, Thailand, 2022-2023.Human vaccines & immunotherapeutics · 2025Article
- Cancer Burden Across The South East Asia Nation (ASEAN) in 2022.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Effects of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis for chemotherapy-induced febrile neutropenia in diffuse large B-cell lymphoma patients receiving the R-CHOP-21 regimen.Asian biomedicine : research, reviews and news · 2025Article
- Molecular and serological investigation of hepatitis B virus in patients with acute undifferentiated febrile illness at Tha Song Yang hospital, Tak Province, Thailand.BMC infectious diseases · 2025Article
- Significant reduction in Hepatitis B virus infections following 32 years of universal Hepatitis B vaccination as part of EPI, Thailand.Scientific reports · 2025Article
- Hepatitis B Vaccine Nonresponse and Associated Risk Factors: Insights From a Cohort Study.Journal of tropical medicine · 2025Article
- Hepatitis B prevalence in an endemic area of hepatitis C virus: A population-based study implicated in hepatitis elimination in Thailand.Journal of virus eradication · 2024Article
- Factors Associated with Hepatocellular Carcinoma among Patients Receiving Treatment at the National Cancer Institute, Thailand: A Case-Control Study.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Article
- A Comprehensive Review of Hepatitis B Vaccine Nonresponse and Associated Risk Factors.Vaccines · 2024Review
- COVID-19 impact on blood donor characteristics and seroprevalence of transfusion-transmitted infections in southern Thailand between 2018 and 2022.Scientific reports · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand's Expanded Program on Immunization (EPI), and extended to the whole country in 1992. Our previous studies showed that children and adolescents who were born after the implementation of this program had a carrier rate of less than 1%, compared with 5-6% before implementation. In 2014 we performed hepatitis B serosurveys among 5964 subjects in the different geographic regions of the country to evaluate the long-term immunogenicity and impact of universal hepatitis B vaccination in newborns as part of the 22-year EPI program, by assessing HBsAg, anti-HBc and anti-HBs seropositivity status. The number of HB virus (HBV) carriers, both children and young adults, who were born after universal HB vaccination was markedly reduced. The carrier rates among the age groups 6 months to 5 years, 5-10, 11-20, 21-30, 31-40, 41-50 and >50 years were respectively 0.1, 0.29, 0.69, 3.12, 3.78, 4.67 and 5.99%. The seropositivity rate for HBsAg in the post-EPI group was 0.6%, whereas in the pre-EPI group it was as high as 4.5% (p<0.001). HBV infection by means of detectable anti-HBc had also drastically declined in the population born after the HB vaccine was integrated into the EPI program. We estimated that the total number of HBV carriers amounted to 2.22 million, or 3.48% of the total population, most of whom are adults. The HB vaccine is the first vaccine shown to be effective in preventing the occurrence of chronic liver disease and hepatocellular carcinoma. Universal vaccination campaign will contribute to the eventual eradication of HBV-associated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.